{
  "id": 20924185,
  "title": "KRAS at Triple Meeting: Erasca wants to one-up RevMed, while Alterome tries a different approach",
  "url": "https://urgent.news/2026/11/20/kras-at-triple-meeting-erasca-wants-to-one-up-revmed-while-alterome",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-20T16:22:25.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/kras-at-triple-meeting-erasca-wants-to-one-up-revmed-while-alterome-tries-a-different-approach/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Revolution Medicines posted strong data on its targeted pancreatic cancer drug Thursday evening, but competition is building at every turn in the KRAS field. RevMed’s game-changing pan-RAS drug Rasonque (daraxonrasib) alongside ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}